Diffuse Alveolar Hemorrhage in Autoimmune Diseases
Purpose of Review The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome. Recent Findings Recent studies found a frequent association between DAH and infections an...
Gespeichert in:
| Veröffentlicht in: | Current rheumatology reports 2017-05, Vol.19 (5), p.27-27, Article 27 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 27 |
|---|---|
| container_issue | 5 |
| container_start_page | 27 |
| container_title | Current rheumatology reports |
| container_volume | 19 |
| creator | Martínez-Martínez, Marco Ulises Oostdam, David Alejandro Herrera-van Abud-Mendoza, Carlos |
| description | Purpose of Review
The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome.
Recent Findings
Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis.
Summary
Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment. |
| doi_str_mv | 10.1007/s11926-017-0651-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1886752589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1886752589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-b26d78786571f4e33b98c355b5d66340fa49baa7690387c84d77747a26b95aa23</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-AC-So5fV_f44llatUPCi52WTTGpKkq27jdB_b0qqR08zMM-8zDwI3VLyQAnRj4lSyxQmVGOiJMWHMzSlkgusONHnx55xzLUWE3SV0pYQRojhl2jCDLeaMjlFbFlXVZ8gmzffEBofsxW0IcZPv4Gs7rJ5vw912_YdZMs6gU-QrtFF5ZsEN6c6Qx_PT--LFV6_vbwu5mtccCH2OGeq1EYbJTWtBHCeW1NwKXNZKsUFqbywufdaWcKNLowo9XCp9kzlVnrP-Azdj7m7GL56SHvX1qmApvEdhD45aozSkkljB5SOaBFDShEqt4t16-PBUeKOqtyoyg2q3FGVOww7d6f4Pm-h_Nv4dTMAbATSMOo2EN029LEbXv4n9Qdz0XKe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1886752589</pqid></control><display><type>article</type><title>Diffuse Alveolar Hemorrhage in Autoimmune Diseases</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Martínez-Martínez, Marco Ulises ; Oostdam, David Alejandro Herrera-van ; Abud-Mendoza, Carlos</creator><creatorcontrib>Martínez-Martínez, Marco Ulises ; Oostdam, David Alejandro Herrera-van ; Abud-Mendoza, Carlos</creatorcontrib><description>Purpose of Review
The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome.
Recent Findings
Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis.
Summary
Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment.</description><identifier>ISSN: 1523-3774</identifier><identifier>EISSN: 1534-6307</identifier><identifier>DOI: 10.1007/s11926-017-0651-y</identifier><identifier>PMID: 28397125</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality ; Antiphospholipid Syndrome - complications ; Antiphospholipid Syndrome - mortality ; Autoimmune Diseases - complications ; Autoimmune Diseases - mortality ; Hemorrhage - diagnosis ; Hemorrhage - etiology ; Hemorrhage - mortality ; Hemorrhage - therapy ; Humans ; Lung Diseases - diagnosis ; Lung Diseases - etiology ; Lung Diseases - mortality ; Lung Diseases - therapy ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - mortality ; Medicine ; Medicine & Public Health ; Prognosis ; Pulmonary Alveoli ; Rheumatology ; Risk Factors ; Section Editor ; Topical Collection on Vasculitis ; Vasculitis (L Espinoza</subject><ispartof>Current rheumatology reports, 2017-05, Vol.19 (5), p.27-27, Article 27</ispartof><rights>Springer Science+Business Media New York 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-b26d78786571f4e33b98c355b5d66340fa49baa7690387c84d77747a26b95aa23</citedby><cites>FETCH-LOGICAL-c344t-b26d78786571f4e33b98c355b5d66340fa49baa7690387c84d77747a26b95aa23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11926-017-0651-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11926-017-0651-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28397125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez-Martínez, Marco Ulises</creatorcontrib><creatorcontrib>Oostdam, David Alejandro Herrera-van</creatorcontrib><creatorcontrib>Abud-Mendoza, Carlos</creatorcontrib><title>Diffuse Alveolar Hemorrhage in Autoimmune Diseases</title><title>Current rheumatology reports</title><addtitle>Curr Rheumatol Rep</addtitle><addtitle>Curr Rheumatol Rep</addtitle><description>Purpose of Review
The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome.
Recent Findings
Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis.
Summary
Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment.</description><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Antiphospholipid Syndrome - mortality</subject><subject>Autoimmune Diseases - complications</subject><subject>Autoimmune Diseases - mortality</subject><subject>Hemorrhage - diagnosis</subject><subject>Hemorrhage - etiology</subject><subject>Hemorrhage - mortality</subject><subject>Hemorrhage - therapy</subject><subject>Humans</subject><subject>Lung Diseases - diagnosis</subject><subject>Lung Diseases - etiology</subject><subject>Lung Diseases - mortality</subject><subject>Lung Diseases - therapy</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - mortality</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Prognosis</subject><subject>Pulmonary Alveoli</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><subject>Section Editor</subject><subject>Topical Collection on Vasculitis</subject><subject>Vasculitis (L Espinoza</subject><issn>1523-3774</issn><issn>1534-6307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1Lw0AQhhdRbK3-AC-So5fV_f44llatUPCi52WTTGpKkq27jdB_b0qqR08zMM-8zDwI3VLyQAnRj4lSyxQmVGOiJMWHMzSlkgusONHnx55xzLUWE3SV0pYQRojhl2jCDLeaMjlFbFlXVZ8gmzffEBofsxW0IcZPv4Gs7rJ5vw912_YdZMs6gU-QrtFF5ZsEN6c6Qx_PT--LFV6_vbwu5mtccCH2OGeq1EYbJTWtBHCeW1NwKXNZKsUFqbywufdaWcKNLowo9XCp9kzlVnrP-Azdj7m7GL56SHvX1qmApvEdhD45aozSkkljB5SOaBFDShEqt4t16-PBUeKOqtyoyg2q3FGVOww7d6f4Pm-h_Nv4dTMAbATSMOo2EN029LEbXv4n9Qdz0XKe</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Martínez-Martínez, Marco Ulises</creator><creator>Oostdam, David Alejandro Herrera-van</creator><creator>Abud-Mendoza, Carlos</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Diffuse Alveolar Hemorrhage in Autoimmune Diseases</title><author>Martínez-Martínez, Marco Ulises ; Oostdam, David Alejandro Herrera-van ; Abud-Mendoza, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-b26d78786571f4e33b98c355b5d66340fa49baa7690387c84d77747a26b95aa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Antiphospholipid Syndrome - mortality</topic><topic>Autoimmune Diseases - complications</topic><topic>Autoimmune Diseases - mortality</topic><topic>Hemorrhage - diagnosis</topic><topic>Hemorrhage - etiology</topic><topic>Hemorrhage - mortality</topic><topic>Hemorrhage - therapy</topic><topic>Humans</topic><topic>Lung Diseases - diagnosis</topic><topic>Lung Diseases - etiology</topic><topic>Lung Diseases - mortality</topic><topic>Lung Diseases - therapy</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - mortality</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Prognosis</topic><topic>Pulmonary Alveoli</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><topic>Section Editor</topic><topic>Topical Collection on Vasculitis</topic><topic>Vasculitis (L Espinoza</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez-Martínez, Marco Ulises</creatorcontrib><creatorcontrib>Oostdam, David Alejandro Herrera-van</creatorcontrib><creatorcontrib>Abud-Mendoza, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current rheumatology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez-Martínez, Marco Ulises</au><au>Oostdam, David Alejandro Herrera-van</au><au>Abud-Mendoza, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diffuse Alveolar Hemorrhage in Autoimmune Diseases</atitle><jtitle>Current rheumatology reports</jtitle><stitle>Curr Rheumatol Rep</stitle><addtitle>Curr Rheumatol Rep</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>19</volume><issue>5</issue><spage>27</spage><epage>27</epage><pages>27-27</pages><artnum>27</artnum><issn>1523-3774</issn><eissn>1534-6307</eissn><abstract>Purpose of Review
The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome.
Recent Findings
Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis.
Summary
Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28397125</pmid><doi>10.1007/s11926-017-0651-y</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3774 |
| ispartof | Current rheumatology reports, 2017-05, Vol.19 (5), p.27-27, Article 27 |
| issn | 1523-3774 1534-6307 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1886752589 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - mortality Antiphospholipid Syndrome - complications Antiphospholipid Syndrome - mortality Autoimmune Diseases - complications Autoimmune Diseases - mortality Hemorrhage - diagnosis Hemorrhage - etiology Hemorrhage - mortality Hemorrhage - therapy Humans Lung Diseases - diagnosis Lung Diseases - etiology Lung Diseases - mortality Lung Diseases - therapy Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - mortality Medicine Medicine & Public Health Prognosis Pulmonary Alveoli Rheumatology Risk Factors Section Editor Topical Collection on Vasculitis Vasculitis (L Espinoza |
| title | Diffuse Alveolar Hemorrhage in Autoimmune Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A50%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diffuse%20Alveolar%20Hemorrhage%20in%20Autoimmune%20Diseases&rft.jtitle=Current%20rheumatology%20reports&rft.au=Mart%C3%ADnez-Mart%C3%ADnez,%20Marco%20Ulises&rft.date=2017-05-01&rft.volume=19&rft.issue=5&rft.spage=27&rft.epage=27&rft.pages=27-27&rft.artnum=27&rft.issn=1523-3774&rft.eissn=1534-6307&rft_id=info:doi/10.1007/s11926-017-0651-y&rft_dat=%3Cproquest_cross%3E1886752589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1886752589&rft_id=info:pmid/28397125&rfr_iscdi=true |